Hepatic arterial infusion (HAI) of oxaliplatin with capecitabine in first line treatment of patients (pts) with liver limited metastases from colorectal cancer (LLmCRC)

Antitumour immunity invoked by hepatic arterial infusion of first‐line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8–12 years of follow‐up

“…44,45 The current study population displayed distributions of age, sex and tumour sidedness and mutational status in agreement with other reports on isolated CLM. 37 Oxaliplatin-based chemotherapy administered systemically is considered the standard-of-care for the majority of CLM patients, particularly if conversion of technically unresectable disease to resectability is the primary goal. The significantly longer overall survival for those patients has been reported previously.…”

“…The significantly longer overall survival for those patients has been reported previously. 37 Oxaliplatin-based chemotherapy administered systemically is considered the standard-of-care for the majority of CLM patients, particularly if conversion of technically unresectable disease to resectability is the primary goal. 10 Prospective studies of oxaliplatin-HAI in combination with a systemically administered fluoropyrimidine, given either as early-line therapy or after failure of systemic palliative therapy, have reported various response and survival rates.…”

“…37 As delineated in Figure 1, patients were given a dose-intensified regimen of HAI-oxaliplatin (100 mg/m 2 ) on Day 1 and high-dose oral capecitabine (1,750 mg/m 2 twice daily) on Day 1-7 every 2 weeks for a maximum of 12 cycles, in accordance with a dose administration regimen described in 2003. 37 As delineated in Figure 1, patients were given a dose-intensified regimen of HAI-oxaliplatin (100 mg/m 2 ) on Day 1 and high-dose oral capecitabine (1,750 mg/m 2 twice daily) on Day 1-7 every 2 weeks for a maximum of 12 cycles, in accordance with a dose administration regimen described in 2003.…”

“…In this nonrandomised phase 2 study, eligible patients presented with their first recurrence of oxaliplatin-naïve isolated CLM originating from CRC adenocarcinoma and considered technically unresectable. 37 As delineated in Figure 1, patients were given a dose-intensified regimen of HAI-oxaliplatin (100 mg/m 2 ) on Day 1 and high-dose oral capecitabine (1,750 mg/m 2 twice daily) on Day 1-7 every 2 weeks for a maximum of 12 cycles, in accordance with a dose administration regimen described in 2003. 38 The study treatment was terminated sooner if patients experienced intolerable toxicity or disease progression, or after 8 cycles if objective radiographic response had failed to occur.…”

“…Patients with CLM that did not become resectable via the study treatment proceeded to irinotecan-based chemotherapy. CLM resectability (resectable or unresectable), irrespective of the number of HAI cycles, was the primary end point (along with the response rate 37 ). The overall survival rate at censoring, recorded on the 8th of February, 2018, was a secondary end point.…”